Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China - 22/11/17
, Kang-lin Wan a, ⁎ Abstract |
Rapid detection of resistance to the second-line drugs is essential for early initiation of appropriate anti-tubercular treatment regimen among multi-drug tuberculosis (MDR-TB). In this study, we applied a multiplex allele-specific PCR (MAS-PCR) to identify the mutations on codons 90 and 94 of gyrA and nucleotide 1401 of rrs for detecting ofloxacin (OFX) and kanamycin (KAN) resistance in 139 MDR-TB isolates from China. Using the traditional phenotypic method as the reference, MAS-PCR detected resistance to OFX and KAN with sensitivities of 67.3% and 76.5%, respectively, and specificities of 100.0%. Therefore, MAS-PCR assays can be used for rapid detection of second-line drug resistance among MDR-TB in China, enabling early administration of appropriate treatment regimens to the affected MDR-TB patients.
Le texte complet de cet article est disponible en PDF.Keywords : Multiplex allele specific PCR, Multidrug-resistant tuberculosis, Ofloxacin, Kanamycin
Plan
Vol 107
P. 1-4 - décembre 2017 Retour au numéro
Article précédent
- CISH controls bacterial burden early after infection with Mycobacterium tuberculosis in mice
- Berit Carow, Yu Gao, Graciela Terán, Xuexian O. Yang, Chen Dong, Akihiko Yoshimura, Martin E. Rottenberg
- Host blood RNA signatures predict the outcome of tuberculosis treatment
- Ethan G. Thompson, Ying Du, Stephanus T. Malherbe, Smitha Shankar, Jackie Braun, Joe Valvo, Katharina Ronacher, Gerard Tromp, David L. Tabb, David Alland, Shubhada Shenai, Laura E. Via, James Warwick, Alan Aderem, Thomas J. Scriba, Jill Winter, Gerhard Walzl, Daniel E. Zak, the Catalysis TB–Biomarker Consortium, Nelita Du Plessis, Andre G. Loxton, Novel N. Chegou, Myungsun Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?